Article Content

The FDA approved the use of oseltamivir (Tamiflu, Roche Pharmaceuticals) for prevention of seasonal influenza in children 1 to 12 years of age who had close contact with an infected individual. It is the first drug approved for prevention of both influenza A and B in pediatric patients. It was previously approved for both prevention and treatment of influenza in adolescents 13 years of age and older and in adults. Oseltamivir is also approved for treatment of influenza in pediatric patients older than 1 year of age.


Dosing is based on weight and lasts 10 days. Treatment should be started within 2 days of close contact with an infected individual.


The FDA notes that oseltamivir is not a substitute for flu vaccination; patients should continue receiving annual flu shots according to immunization guidelines.


Consult product labeling for information on safety and side effects associated with oseltamivir.

FIGURE. No caption a... - Click to enlarge in new windowFIGURE. No caption available.